Joshua Calvert, MD
Urology · Nashville, TNNPI 1629424585
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Procept Biorobotics Corporation at 31.4% of the total. 2025 is the largest year on record at $12,718, 7.5 times the $1,685 reported in 2021.
Across 239 payments — averaging $96.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$7K
- Tolmar, Inc.$6K
- Boston Scientific$5K
- Coloplast$2K
- Sumitomo Pharma America, Inc.$480
- Innovation Technologies Inc$245
- plus $2K from 26 others
What the payments were for
- Consulting fees$11,39850%
- Travel & lodging$4,05518%
- Food & beverage$7,36532%
- Education$1801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 14 | $7,210 |
| Tolmar, Inc. | 34 | $5,934 |
| Boston Scientific | 75 | $4,947 |
| Coloplast | 27 | $2,143 |
| Sumitomo Pharma America, Inc. | 24 | $480 |
| Innovation Technologies Inc | 3 | $245 |
| Halozyme Inc | 6 | $217 |
| SRS Medical Systems, Inc. | 1 | $197 |
| Olympus America Inc. | 2 | $187 |
| Medtronic | 2 | $158 |
| Antares Pharma, Inc. | 13 | $136 |
| Merck | 3 | $131 |
| Johnson & Johnson | 1 | $124 |
| Astellas Pharma US Inc | 4 | $119 |
| Endo Pharmaceuticals Inc. | 1 | $117 |
| AbbVie | 3 | $82 |
| Teleflex LLC | 1 | $72 |
| Laborie Medical Technologies Corp. | 5 | $65 |
| Verity Pharmaceuticals Inc. | 3 | $58 |
| Urogen Pharma, Inc. | 2 | $43 |
| Agiliti Health, Inc. | 1 | $43 |
| Acerus Pharmaceuticals Corporation | 1 | $42 |
| Pfizer | 2 | $37 |
| Urovant Sciences Inc | 2 | $36 |
| Azurity Pharmaceuticals, Inc. | 2 | $35 |
| Axonics, Inc. | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Dendreon Pharmaceuticals LLC | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Endo USA, Inc. | 1 | $16 |
| AstraZeneca | 1 | $14 |
| Myovant Sciences Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$6,832
- JATENZO$5,451
- AMS 700 CXR RTE KIT$1,738
- TITAN$1,467
- GENERAL ERECTILE DYSFUNCTION$236
- AQUABEAM SYSTEM$231
- AMS 700$221
- CT3000 Pro Base Unit$197
- UroCuff-DC Disposable, Single$197
- XYOSTED$169
- Irrisept$142
- iTIND System$141
- LigaSure$132
- Erleada$124
- XIAFLEX$117
- TACTRA$111
- Tria Firm$102
How this compares
$22,997 in reported general payments places this provider in the 85th percentile of 276 urology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 77 | $61,760 |
| MyrbetriqMirabegron | 34 | $30,951 |
| Testosterone Cypionate | 154 | $6,540 |
| Testosterone | 22 | $3,873 |
| Tamsulosin Hcl | 237 | $2,810 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 38 | $1,373 |
| Finasteride | 104 | $1,354 |
| Estradiol | 11 | $872 |
| Testosterone Enanthate | 11 | $683 |
| Potassium Citrate ErPotassium Citrate | 11 | $643 |
| Dutasteride | 29 | $452 |
| Sildenafil Citrate | 11 | $428 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 34 | $422 |
| Ciprofloxacin Hcl | 24 | $168 |
| Oxybutynin Chloride | 34 | $162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $480 | $61,76077 claims |
| Astellas Pharma US IncMyrbetriq | $119 | $30,95134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 276 urology providers in Tennessee.
Other urology in Nashville
- L KnollNashville$2.1M
- Gautam JayramNashville$1M
- Roger DmochowskiNashville$763K
- Ashley TapscottNashville$425K
- Raoul ConcepcionNashville$339K
- Melissa KaufmanNashville$312K
- Sam ChangNashville$198K
- Benjamin DehnerNashville$165K
- Smita deNashville$100K
- Nicole MillerNashville$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.